Sino Biopharmaceutical Limited announces that the Group entered into a strategic partnership with Boehringer Ingelheim to bring Boehringer Ingelheim's innovative cancer therapies to the market in mainland China. Under the agreement, the Group and Boehringer Ingelheim (the "Parties") will collaborate to jointly develop and commercialize Boehringer Ingelheim's oncology pipeline in mainland China. The strategic partnership covers multiple assets under clinical development by Boehringer Ingelheim, including three assets brigimadlin, zongertinib, and BI 764532, and multiple early-stage assets.

The Parties will join efforts to bring these oncology products to patients in mainland China, with the Group consolidating the revenue for the products in China. Brigimadlin is a mouse double minute 2 (MDM2)-p53 antagonist which has advanced into the pivotal trial for the treatment of dedifferentiated liposarcoma (DDLPS) and is being investigated for other cancers such as biliary tract cancer (BTC), non-small cell lung cancer (NSCLC), pancreatic cancer and other tumors with MDM2 amplifications. Zongertinib is a selective human epidermal growth factor receptor 2 (HER2) inhibitor that covalently binds to the tyrosine kinase domain (TKD) of both wild type and mutated HER2 receptors, including those with an exon 20 mutation.

Improved selectivity of a HER2 tyrosine kinase inhibitor (TKI) may result in better tolerability and efficacy. BI 764532 is a delta-like canonical Notch ligand 3/cluster of differentiation 3 (DLL3/CD3) bispecific T-cell engager, which is currently in Phase II clinical study investigating for the treatment of small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs). The Group's strategic partnership with Boehringer Ingelheim is of great significance: The strategic partnership is expected to enrich the Group's oncology portfolio with innovation from Boehringer Ingelheim's oncology pipeline, and help fulfill unmet clinical needs in China.

The strategic partnership also expands the Group's horizons, recognizes the Group's strong commercial capabilities, and makes the Group a preferred partner for MNCs. Oncology is the largest therapeutic area of the Group. The agreement marks the beginning of the Group's strategic partnership with Boehringer Ingelheim.